The estimated Net Worth of Michael J. Kaufman is at least $79.1 Thousand dollars as of 15 July 2021. Michael Kaufman owns over 40,000 units of Mersana Therapeutics Inc stock worth over $79,137 and over the last 7 years he sold MRSN stock worth over $0. In addition, he makes $0 as Senior Vice President - Chemistry and Manufacturing and Controls at Mersana Therapeutics Inc.
Michael has made over 2 trades of the Mersana Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 40,000 units of MRSN stock worth $70,800 on 15 July 2021.
The largest trade he's ever made was exercising 40,000 units of Mersana Therapeutics Inc stock on 15 July 2021 worth over $70,800. On average, Michael trades about 7,778 units every 30 days since 2018. As of 15 July 2021 he still owns at least 44,710 units of Mersana Therapeutics Inc stock.
You can see the complete history of Michael Kaufman stock trades at the bottom of the page.
Dr. Michael Kaufman Ph.D. serves as Senior Vice President - Chemistry, Manufacturing and Controls of the Company. Previously, from 2012 to 2016, Dr. Kaufman served as Vice President, Technical Development at Biogen, Inc. Before Biogen, Dr. Kaufman spent 10 years at Millennium Pharmaceuticals, prior to and after it became a wholly owned subsidiary of Takeda Pharmaceuticals, most recently as Vice President, Pharmaceutical Sciences. Before that, he spent 15 years at Merck and Co., Inc. serving in various roles. Dr. Kaufman received a B.S. in Chemistry from the State University of New York, Stony Brook and a Ph.D. in Physical Organic Chemistry from the University of California, Berkeley.
Michael Kaufman is 62, he's been the Senior Vice President - Chemistry and Manufacturing and Controls of Mersana Therapeutics Inc since 2016. There are 2 older and 18 younger executives at Mersana Therapeutics Inc. The oldest executive at Mersana Therapeutics Inc is Lawrence Alleva, 70, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 7 years, insiders at Mersana Therapeutics Inc have traded over $1,068,087 worth of Mersana Therapeutics Inc stock and bought 26,457,775 units worth $226,822,416 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Mersana Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $534,621. The most recent stock trade was executed by Anna Protopapas on 13 January 2024, trading 86,958 units of MRSN stock currently worth $153,916.
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
Mersana Therapeutics Inc executives and other stock owners filed with the SEC include: